Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

PAX5

  • Home
  • PAX5
Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
Posted inHematology-Oncology news

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Posted by MedXY By MedXY 06/02/2026
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
Read More
  • Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma
  • Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
  • Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
  • CT Small-Artery Loss Tracks Severe Pulmonary Hypertension in COPD and Fibrosing ILD More Closely Than Parenchymal Damage
  • International Validation of Electronic Nose Technology as a Diagnostic Tool for Fibrotic Interstitial Lung Diseases
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in